Vice President - Corporate Controller
About the job
- A bachelor's degree in Accounting is required.
- Certified Public Accountant certification is required.
- At least 15 years of progressive accounting and finance experience is required.
- At least 8 years of leadership experience, including responsibility for building and leading accounting teams, is required.
- Public-company accounting and Securities and Exchange Commission reporting experience is required.
- Strong experience with Sarbanes-Oxley Act Section 404 and internal control environments is required.
- Pharmaceutical, biotechnology, or life sciences industry experience is required.
- Commercial biopharmaceutical accounting experience is required.
- Lead all accounting operations and monthly, quarterly, and annual close processes.
- Ensure timely and accurate financial reporting in accordance with U.S. Generally Accepted Accounting Principles.
- Maintain and continuously strengthen accounting policies, procedures, and internal controls.
- Oversee the general ledger, consolidation, reconciliations, and related accounting processes.
- Drive continuous improvement and efficiency across the close process.
- Ensure the accounting organization and infrastructure support the transition from pre-commercial to commercial operations.
- Build scalable capabilities supporting multiple commercial products, development-stage assets, organizational and geographic expansion, business development activities, and mergers and acquisitions integration.
- Provide executive oversight for commercial accounting, including revenue recognition under Accounting Standards Codification 606, product sales and specialty pharmacy/distribution accounting, gross-to-net accounting, chargebacks, rebates, product returns, distribution fees, patient assistance and copay programs, and government programs such as Medicaid and 340B.
- Ensure gross-to-net reserves and methodologies are accurate, defensible, appropriately controlled, and well documented.
- Partner with Commercial Finance, Market Access, Government Pricing, Trade and Distribution, Financial Planning and Analysis, and other stakeholders on financial reporting and launch readiness.
- Lead accounting activities supporting manufacturing, supply chain, and commercial distribution.
- Establish scalable inventory and costing processes for commercialization and future growth.
- Provide leadership and technical accounting guidance for business development transactions, asset acquisitions, licensing and collaboration agreements, milestone payments, royalties, mergers and acquisitions, impairments, equity compensation, and debt and financing arrangements.
- Prepare or oversee accounting position papers, technical accounting memoranda, and supporting documentation for auditors and management.
- Provide leadership and oversight for accounting activities supporting clinical development and research, including clinical trial accruals, contract research organization accounting, investigator and site payments, clinical and development obligations, collaborations, licensing, milestones, royalties, and development-stage manufacturing.
- Oversee shared accounting operations supporting Accounts Payable, Payroll, Equity Administration, and related corporate accounting activities.
- Lead and continuously strengthen the company's Sarbanes-Oxley and internal control environment.
- Oversee risk assessments, control design, process documentation, control testing, deficiency identification and remediation, segregation of duties, and audit coordination.
- Build a sustainable internal control framework for a larger, more complex commercial-stage organization.
- Partner with Finance, Information Technology, Commercial Operations, and other functions to develop scalable financial infrastructure and systems.
- Provide accounting leadership and requirements for enterprise resource planning, revenue management, gross-to-net, inventory and supply chain, consolidation, and financial reporting and analytics platforms.
- Lead and support system implementations, automation, and process transformation initiatives.
- Build, lead, and develop a high-performing accounting organization.
- Establish an organizational structure supporting commercial growth and increasing complexity.
- Recruit and develop accounting and finance talent.
- Establish performance expectations, development plans, and succession strategies.
- Serve as a trusted advisor and business partner to Finance leadership and the broader organization.
- Experience supporting a pharmaceutical or biotechnology product launch is strongly preferred.
- Experience scaling an accounting organization from pre-commercial through commercial stage is strongly preferred.
- Public accounting experience is preferred.
- An MBA or advanced degree is preferred.
About the company
Celldex develops antibody-based therapies for inflammatory, allergic, and autoimmune diseases, focusing on mast cell biology. Its lead program barzolvolimab is a humanized monoclonal antibody that blocks KIT signaling to reduce mast cell activity and inflammation, with additional antibodies in development that engage the immune system or modulate disease pathways. It differentiates itself by concentrating on KIT/mast cell biology within antibody therapies and pursuing a mix of partnerships, licensing, and own products. Its goal is to bring therapies to patients that lower inflammation and autoimmunity by targeting mast cells and related pathways.
Company Size
201-500
Company Stage
IPO
Headquarters
Hampton, New Jersey
Founded
1983
Get referred to Celldex Therapeutics
See people who can refer or advise you
Simplify's Take
What believers are saying
- Sept. 22, 2026 Phase 3 EMBARQ-CSU1 and CSU2 met all primary endpoints.
- June 30, 2026 cash reached $717.6 million after April's $323.8 million offering.
- Management plans a 2027 BLA submission, creating a near-term regulatory catalyst.
What critics are saying
- July 2026 prurigo nodularis failure killed one barzolvolimab growth path immediately.
- Aug. 24, 2026 shareholder investigation threatens governance distraction and litigation costs.
- One program, barzolvolimab, still drives value; a CSU safety setback would cripple Celldex.
What makes Celldex Therapeutics unique
- Barzolvolimab targets KIT-positive mast cells, a mechanism few allergy drugs attack directly.
- Phase 3 EMBARQ-CSU enrolled 1,939 patients, giving Celldex unusually deep CSU data.
- CDX-622 combines TSLP neutralization with mast-cell depletion, broadening its immunology platform.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Paid Holidays
Paid Vacation
Paid Sick Leave
401(k) Retirement Plan
Growth & Insights and Company News
6 month growth
12%1 year growth
12%2 year growth
12%Celldex Therapeutics (NASDAQ: CLDX) Price Target Soars on Positive Phase III clinical trial results. Sep 23, 2026 Market News FMPCelldex Therapeutics (NASDAQ: CLDX) Price Target Soars on Positive Phase III Cli... * Leerink Partners significantly raised its price target for Celldex Therapeutics to $88.00, indicating strong analyst confidence in the biotechnology stock. * Celldex reported successful Phase III clinical trial results for its drug barzolvolimab in treating chronic spontaneous urticaria (CSU), meeting all primary endpoints. * Despite the positive news regarding CSU, the Celldex stock price experienced a slight decline following the discontinuation of a separate Phase 2 trial for barzolvolimab in another condition. Celldex Therapeutics (NASDAQ: CLDX) is a leading biotechnology stock that develops innovative therapies to treat specific diseases. With a market capitalization of around $2.1 billion, the company focuses on creating targeted treatments through advanced drug development. Its main drug candidate is barzolvolimab, which is being studied for several conditions. On September 23, 2026, Thomas Smith of Leerink Partners increased the price target for Celldex Therapeutics to $88.00 from $70.00. A price target is an analyst's projection of a stock's future price, crucial for stock analysis. At the time, the stock was trading at $31.19, showing significant potential upside according to the analyst. This optimism follows positive results from Celldex's Phase III clinical trials for barzolvolimab. The drug is designed for adults with chronic spontaneous urticaria (CSU), a skin condition, who do not get better with antihistamines. The studies, EMBARQ-CSU1 and EMBARQ-CSU2, met all their main goals, highlighting progress in CSU treatment. The trials showed that barzolvolimab was effective and that its benefits lasted or even improved over 24 weeks. As highlighted by Defense World, these global trials included 1,939 patients. Celldex now plans to submit a Biologics License Application (BLA) in 2027, a key step towards potential FDA approval for the new drug. However, as reported by Benzinga, Celldex also stopped a separate Phase 2 trial of barzolvolimab for a different condition after it failed to meet its goals. Despite the positive CSU news, the Celldex stock price decreased by 6.03% to $31.49 during the day's trading. Market news and analyst rating coverage Andrew Wynn writes market news and analyst-rating coverage for the FMP blog, tracking price-target revisions, broker upgrades and downgrades, and earnings developments across U.S. equities. His posts distill fast-moving market events into clear, factual summaries grounded in financial data. Financial data for every need. Real-time quotes and 30+ years of historical data, including prices, fundamentals, and insider transactions - all accessible via API. Stock Screener 2017-2026 (C) FMP
Celldex Therapeutics (NASDAQ:CLDX) given new $50.00 price target at Morgan Stanley. September 10, 2026 Key points. * Morgan Stanley raised its price target for Celldex Therapeutics to $50 from $46 and maintained an "overweight" rating, implying approximately 29.5% upside from the prior close. * Analyst sentiment is broadly positive: Celldex has a consensus "Moderate Buy" rating and an average price target of $56.42, although targets range widely from $42 to $100. * Shares fell 0.4% to $38.62 in Thursday trading. Celldex recently reported a quarterly loss of $0.94 per share, which was better than the expected $1.06 loss, but revenue of $0.02 million came in below expectations. * Five stocks we like better than Celldex Therapeutics. Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) had its target price lifted by Morgan Stanley from $46.00 to $50.00 in a research note issued on Thursday, Benzinga reports. The brokerage currently has an "overweight" rating on the biopharmaceutical company's stock. Morgan Stanley's price target points to a potential upside of 29.48% from the company's previous close. Several other analysts have also recently weighed in on the stock. Wall Street Zen raised shares of Celldex Therapeutics from a "strong sell" rating to a "sell" rating in a report on Sunday, July 12th. HC Wainwright reiterated a "buy" rating and set a $42.00 price target on shares of Celldex Therapeutics in a report on Monday, June 15th. Cantor Fitzgerald dropped their price objective on shares of Celldex Therapeutics from $67.00 to $61.00 and set an "overweight" rating on the stock in a research report on Wednesday, July 22nd. Guggenheim raised their price objective on shares of Celldex Therapeutics from $90.00 to $100.00 and gave the company a "buy" rating in a report on Monday, July 20th. Finally, UBS Group lifted their price objective on shares of Celldex Therapeutics from $38.00 to $45.00 and gave the stock a "buy" rating in a research report on Wednesday, June 10th. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Celldex Therapeutics has a consensus rating of "Moderate Buy" and a consensus price target of $56.42. Celldex Therapeutics trading down 0.4%. NASDAQ:CLDX traded down $0.17 during midday trading on Thursday, reaching $38.62. The company had a trading volume of 221,694 shares, compared to its average volume of 931,862. Celldex Therapeutics has a 12-month low of $22.10 and a 12-month high of $45.14. The firm has a market capitalization of $3.03 billion, a price-to-earnings ratio of -8.88 and a beta of 0.84. The stock's fifty day simple moving average is $39.19 and its 200-day simple moving average is $34.22. Discover more Stock split calculator Stock profit calculator Stock market news Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.94) earnings per share for the quarter, topping the consensus estimate of ($1.06) by $0.12. The company had revenue of $0.02 million for the quarter, compared to analysts' expectations of $0.73 million. As a group, sell-side analysts expect that Celldex Therapeutics will post -4.17 EPS for the current year. Hedge funds weigh in on Celldex Therapeutics. Hedge funds have recently added to or reduced their stakes in the stock. Wilmington Savings Fund Society FSB acquired a new position in shares of Celldex Therapeutics in the 3rd quarter valued at $42,000. Russell Investments Group Ltd. raised its stake in Celldex Therapeutics by 27.6% during the 2nd quarter. Russell Investments Group Ltd. now owns 2,315 shares of the biopharmaceutical company's stock worth $47,000 after acquiring an additional 501 shares in the last quarter. Quantbot Technologies LP acquired a new stake in Celldex Therapeutics during the 3rd quarter worth $63,000. Nykredit A S purchased a new stake in Celldex Therapeutics in the second quarter valued at $67,000. Finally, Kestra Advisory Services LLC acquired a new position in Celldex Therapeutics in the fourth quarter valued at $98,000. Celldex Therapeutics company profile. Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company's research platforms leverage novel antibody and vaccine technologies designed to engage the patient's immune system, with a particular emphasis on oncology and neurologic indications. Celldex's pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity. Among Celldex's lead product candidates is glembatumumab vedotin, an antibody-drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider Celldex Therapeutics, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Celldex Therapeutics wasn't on the list. While Celldex Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow. Continue following MarketBeat
Celldex to present at upcoming Investor Conference. HAMPTON, N.J., Sept. 08, 2026 (GLOBE NEWSWIRE) - Celldex (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the upcoming Cantor Global Healthcare Conference on September 10, 2026 at 8:00am ET. The webcast of the presentation will be available on the "Events and Presentations" page of the "Investors" section of the Celldex Website. Replays will be available for 90 days following the event. About Celldex Celldex is pioneering new horizons in immunology to deliver life-changing therapies. We are relentless in our pursuit of novel antibody-based treatments that engage the human immune system and directly affect critical pathways to improve the lives of patients with allergic, inflammatory and autoimmune disorders. Visit www.celldex.com. Company Contacts Sarah Cavanaugh Senior Vice President, Corporate Affairs & Administration (508) 864-8337 [email protected] Elizabeth Higgins Executive Director, Investor Relations & Corporate Communications (857) 404-2088 [email protected]
Celldex faces shareholder probe over directors' duties. Celldex under the microscope: A shareholder scoop. Well, look at that. Another day, another company feeling the burn of shareholder scrutiny. Today's star is Celldex Therapeutics, Inc. How'd they get in the crosshairs? Some clever folks at Purcell & Lefkowitz LLP decided it was time to turn up the heat over potential breaches of fiduciary duties by the company's directors. It seems someone's been doing their homework, and NASDAQ:CLDX is on the radar. Digging into the details. So what's got folks digging through the financial dirt? Purcell & Lefkowitz have launched an investigation to see if anything's rotten behind the boardroom doors at Celldex. They've thrown the spotlight on whether the people in power have dropped the ball on their responsibilities to the shareholders. Pure thought: Did these directors think they'd get away with it? Or are Investors Hangout, LLC looking at another classic corporate misstep? The real kicker for investors is digesting how all this could unfurl. Might be just a stern talking-to, or it could blow wide open, shaking things up for the stock. Either way, better buckle up, because the ride's about to get bumpy. What's at Stake for the Market? For those with skin in the game, the concern is real. NASDAQ:CLDX isn't just a ticker - it's your hard-earned bucks potentially on the line. If this investigation escalates, question marks loom over financials, strategic directions, or even personnel changes. Remember, the market's got a way of smelling uncertainty from miles away. If the bigwigs aren't putting their best foot forward, things could get hairy with the stock price. Gossip in the trading room won't help, but solid answers will. The investor's gameplan. If you're holding onto CLDX stock, it might be time to reassess what you've got in that portfolio. Look into the legal nitty-gritty and don't ignore those gut feelings. Knowledge is power. Know who represents your interests and don't shy away from getting some legal advice. Firms like Purcell & Lefkowitz live for this game. * Be informed: Follow the investigation closely, attending briefings if possible. * Evaluate your position: Dive into your strategy to see if holding, selling, or buying more fits your risk appetite. * Legal rights: Touch base with legal experts if you're unsure about what's next. This whole investigation routine might feel like tiptoeing over thin ice, but such is the nature of playing in the capital market arena. The bigger picture and final thoughts. No one's saying it's time to jump ship, but clearly, it's not all smooth sailing for Celldex. Fiduciary duty breaches can haunt a company, stirring up more than just legal headaches - they can wreak havoc on trust, both in the market and among investors. The coming days will be telling. Investors will be keeping a sharp eye on any developments coming down the pipeline. The trust in corporate governance, those necessary evil investigations, and the market's reaction shape up to a crucial narrative for the stakeholders involved. At the heart stands the question: Will Celldex's leadership pull through this intact, or will the aftermath ripple through NASDAQ:CLDX performance? Only time and a lot of legal suspense will tell. So, keep your eyes peeled and your strategies in check.
Celldex Therapeutics reported second-quarter 2026 results showing revenue falling to $0.022 million and net loss widening to $73.5 million. Loss per share from continuing operations increased to $0.94. For the first half of 2026, revenue slipped to just $0.037 million while net loss rose to $152.19 million, highlighting the cost intensity of operations relative to minimal revenue. The company's investment narrative centres on its immunology pipeline, led by barzolvolimab in chronic spontaneous urticaria. The results underscore dependence on clinical and regulatory milestones rather than current sales. Near-term catalysts revolve around late-stage data readouts and the barzolvolimab Phase 3 timeline. The widening gap between spending and revenue sharpens focus on funding needs and potential dilution.